Bank of New York Mellon’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45.1M Buy
553,462
+30,699
+6% +$2.22M 0.01% 1127
2026
Q1
$35.6M Buy
522,763
+8,083
+2% +$572K 0.01% 1208
2025
Q4
$39.1M Buy
514,680
+241,604
+88% +$17.6M 0.01% 1159
2025
Q3
$16.8M Buy
273,076
+6,905
+3% +$360K ﹤0.01% 1637
2025
Q2
$13M Buy
266,171
+49,728
+23% +$2.36M ﹤0.01% 1748
2025
Q1
$11M Sell
216,443
-439
-0.2% -$21.9K ﹤0.01% 1807
2024
Q4
$9.79M Sell
216,882
-1,315
-0.6% -$56.3K ﹤0.01% 1934
2024
Q3
$8.1M Sell
218,197
-60,852
-22% -$2.04M ﹤0.01% 2045
2024
Q2
$8.53M Buy
279,049
+40,840
+17% +$1.32M ﹤0.01% 2044
2024
Q1
$6.93M Sell
238,209
-20,332
-8% -$570K ﹤0.01% 2157
2023
Q4
$7.13M Sell
258,541
-49,069
-16% -$1.12M ﹤0.01% 2191
2023
Q3
$6.89M Sell
307,610
-642,806
-68% -$23.9M ﹤0.01% 2156
2023
Q2
$38.7M Sell
950,416
-14,890
-2% -$729K 0.01% 1174
2023
Q1
$46.8M Sell
965,306
-14,210
-1% -$650K 0.01% 1047
2022
Q4
$37.4M Sell
979,516
-35,778
-4% -$1.49M 0.01% 1168
2022
Q3
$51M Sell
1,015,294
-2,576
-0.3% -$126K 0.01% 946
2022
Q2
$40.8M Sell
1,017,870
-48,525
-5% -$1.7M 0.01% 1114
2022
Q1
$39.8M Sell
1,066,395
-50,081
-4% -$1.93M 0.01% 1249
2021
Q4
$44.5M Sell
1,116,476
-107,751
-9% -$4.12M 0.01% 1246
2021
Q3
$45.6M Buy
1,224,227
+9,630
+0.8% +$396K 0.01% 1193
2021
Q2
$51.3M Buy
1,214,597
+409,436
+51% +$17.5M 0.01% 1120
2021
Q1
$38.1M Buy
805,161
+29,689
+4% +$1.76M 0.01% 1294
2020
Q4
$47.3M Buy
775,472
+31,385
+4% +$1.85M 0.01% 1076
2020
Q3
$34.8M Sell
744,087
-291
-0% -$14.3K 0.01% 1117
2020
Q2
$37.8M Buy
744,378
+397,731
+115% +$19.5M 0.01% 1053
2020
Q1
$15.5M Buy
346,647
+27,527
+9% +$1.39M 0.01% 1442
2019
Q4
$15.3M Buy
319,120
+12,363
+4% +$525K ﹤0.01% 1725
2019
Q3
$10.4M Sell
306,757
-2,539
-0.8% -$111K ﹤0.01% 1908
2019
Q2
$13.9M Buy
309,296
+7,592
+3% +$300K ﹤0.01% 1777
2019
Q1
$11.4M Buy
301,704
+43,700
+17% +$1.47M ﹤0.01% 1901
2018
Q4
$8.85M Buy
258,004
+65,061
+34% +$2.34M ﹤0.01% 1979
2018
Q3
$9.07M Buy
192,943
+7,113
+4% +$294K ﹤0.01% 2074
2018
Q2
$6.27M Buy
185,830
+6,600
+4% +$206K ﹤0.01% 2271
2018
Q1
$4.85M Buy
179,230
+60
+0% +$1.52K ﹤0.01% 2373
2017
Q4
$2.99M Buy
179,170
+7,693
+4% +$130K ﹤0.01% 2612
2017
Q3
$3.43M Buy
171,477
+9,469
+6% +$185K ﹤0.01% 2523
2017
Q2
$2.97M Sell
162,008
-20,040
-11% -$270K ﹤0.01% 2606
2017
Q1
$1.79M Buy
182,048
+20,123
+12% +$244K ﹤0.01% 2913
2016
Q4
$1.77M Sell
161,925
-5,219
-3% -$54.8K ﹤0.01% 2932
2016
Q3
$2.34M Buy
167,144
+17,076
+11% +$139K ﹤0.01% 2658
2016
Q2
$1.05M Buy
150,068
+5,044
+3% +$37K ﹤0.01% 3102
2016
Q1
$934K Sell
145,024
-5,497
-4% -$95.4K ﹤0.01% 3105
2015
Q4
$4.88M Buy
150,521
+6,055
+4% +$178K ﹤0.01% 2225
2015
Q3
$3.86M Sell
144,466
-17,409
-11% -$745K ﹤0.01% 2375
2015
Q2
$7.79M Buy
161,875
+23,009
+17% +$1.34M ﹤0.01% 2091
2015
Q1
$8.45M Sell
138,866
-9,349
-6% -$570K ﹤0.01% 2028
2014
Q4
$7.67M Buy
148,215
+6,038
+4% +$266K ﹤0.01% 2074
2014
Q3
$6.26M Buy
142,177
+1,796
+1% +$56.2K ﹤0.01% 2171
2014
Q2
$3.67M Buy
140,381
+87,261
+164% +$1.87M ﹤0.01% 2508
2014
Q1
$1.39M Buy
53,120
+12,240
+30% +$329K ﹤0.01% 3113
2013
Q4
$693K Buy
40,880
+15,323
+60% +$269K ﹤0.01% 3463
2013
Q3
$548K Buy
+25,557
New +$444K ﹤0.01% 3483

Other funds holding PTCT

Bank of New York Mellon's PTCT Position: Q2 2026 in Review

Bank of New York Mellon increased its PTC Therapeutics (PTCT) stake by 5.9% in Q2 2026, buying an estimated $2.22M and bringing the position to 553,462 shares worth $45.1M. The position accounts for 0.01% of the portfolio, ranked #1127.

Bank of New York Mellon first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $51.3M in Q2 2021. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Bank of New York Mellon held 553,462 shares of PTC Therapeutics worth $45.1M as of Q2 2026.
  • Bank of New York Mellon bought 30,699 PTC Therapeutics shares in Q2 2026, an estimated $2.22M.
  • PTC Therapeutics made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1127 holding.
  • Bank of New York Mellon first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Bank of New York Mellon's PTC Therapeutics position peaked at $51.3M in Q2 2021.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.